Milestones 2003

• Define Therapeutic Focus

  • September 2003

• Initiate Phase 1 clinical trials for ARQ 501

  • September 2003

• Nominate compound from p38 MAP Kinase to GLP-tox by the end of 2003

  • October 2003
    

• Continue to meet all collaborator goals

  • Increased revenue guidance Q3 2003

• Potential progress for partnered compound(s)

Previous slide

Next slide

Back to first slide

View graphic version